Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Femodene ED tablets
0703010F0BJABAG
|
Femodene | Combined ethinylestradiol 30mcg | Obstetrics, Gynaecology and Urinary-Tract Disorders | 361 |
|
Desomono 75microgram tablets
0703021Q0BGAAAA
|
Desomono | Desogestrel | Obstetrics, Gynaecology and Urinary-Tract Disorders | 353 |
|
Cystopurin 3g granules for oral solution sachets
0704030G0BCAAAI
|
Cystopurin (Urological) | Potassium citrate | Obstetrics, Gynaecology and Urinary-Tract Disorders | 332 |
|
Dalacin 2% cream
0702020E0BBAAAA
|
Dalacin | Clindamycin phosphate | Obstetrics, Gynaecology and Urinary-Tract Disorders | 331 |
|
Faramsil 400microgram modified-release tablets (Sandoz)
0704010U0BVAAAB
|
Faramsil | Tamsulosin hydrochloride | Obstetrics, Gynaecology and Urinary-Tract Disorders | 321 |
|
Urispas 200 tablets
0704020G0BBABAC
|
Urispas | Flavoxate hydrochloride | Obstetrics, Gynaecology and Urinary-Tract Disorders | 321 |
|
Canesten 10% vaginal cream
0702020F0BBAGAG
|
Canesten (Vaginal) | Clotrimazole | Obstetrics, Gynaecology and Urinary-Tract Disorders | 314 |
|
Zidoval 0.75% vaginal gel
0702020X0BBAAAA
|
Zidoval | Metronidazole | Obstetrics, Gynaecology and Urinary-Tract Disorders | 312 |
|
Levonelle One Step 1.5mg tablets
0703050A0BCACAB
|
Levonelle | Levonorgestrel | Obstetrics, Gynaecology and Urinary-Tract Disorders | 311 |
|
Sunya 20/75 tablets
0703010E0BHAAAC
|
Sunya | Combined ethinylestradiol 20mcg | Obstetrics, Gynaecology and Urinary-Tract Disorders | 310 |
|
Cialis 2.5mg tablets
0704050R0BBACAC
|
Cialis | Tadalafil | Obstetrics, Gynaecology and Urinary-Tract Disorders | 296 |
|
Gina 10microgram vaginal tablets
0702010G0BGAAAG
|
Gina | Estradiol | Obstetrics, Gynaecology and Urinary-Tract Disorders | 282 |
|
Doralese Tiltab 20mg tablets
0704010M0BBAAAA
|
Doralese Tiltab | Indoramin | Obstetrics, Gynaecology and Urinary-Tract Disorders | 272 |
|
Canesten 200mg pessaries
0702020F0BBADAE
|
Canesten (Vaginal) | Clotrimazole | Obstetrics, Gynaecology and Urinary-Tract Disorders | 269 |
|
Mariosea XL 2mg capsules
0704020N0BDABAI
|
Mariosea XL | Tolterodine | Obstetrics, Gynaecology and Urinary-Tract Disorders | 267 |
|
Yentreve 40mg gastro-resistant capsules
0704020AABBABAB
|
Yentreve | Duloxetine hydrochloride | Obstetrics, Gynaecology and Urinary-Tract Disorders | 266 |
|
Gyno-Pevaryl 150mg vaginal pessaries
0702020H0BCAAAF
|
Gyno-Pevaryl | Econazole nitrate | Obstetrics, Gynaecology and Urinary-Tract Disorders | 264 |
|
Detrusitol 1mg tablets
0704020N0BBAAAA
|
Detrusitol | Tolterodine | Obstetrics, Gynaecology and Urinary-Tract Disorders | 263 |
|
Estradiol 1.5mg / Nomegestrol 2.5mg tablets
0703010S0AAAAAA
|
Estradiol and nomegestrol | Estradiol and nomegestrol | Obstetrics, Gynaecology and Urinary-Tract Disorders | 259 |
|
Muse 500microgram urethral sticks
0704050B0BDADBA
|
Muse | Alprostadil | Obstetrics, Gynaecology and Urinary-Tract Disorders | 258 |
|
Alprostadil 10microgram inj pre-filled disposable devices
0704050B0AABJBJ
|
Alprostadil (Impotence) | Alprostadil | Obstetrics, Gynaecology and Urinary-Tract Disorders | 253 |
|
Alprostadil 40microgram inj cartridges
0704050B0AABFBF
|
Alprostadil (Impotence) | Alprostadil | Obstetrics, Gynaecology and Urinary-Tract Disorders | 250 |
|
Canesten Thrush 500mg Soft Gel pessaries
0702020F0BBARAF
|
Canesten (Vaginal) | Clotrimazole | Obstetrics, Gynaecology and Urinary-Tract Disorders | 244 |
|
Fezolinetant 45mg tablets
0705010A0AAAAAA
|
Fezolinetant | Fezolinetant | Obstetrics, Gynaecology and Urinary-Tract Disorders | 242 |
|
Benilexa One Handed 20microg/24hours delivery system
0703023L0BFAAAA
|
Benilexa | Levonorgestrel | Obstetrics, Gynaecology and Urinary-Tract Disorders | 237 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.